SAN CARLOS, Calif., Nov. 6, 2015 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer, announced today that Ovid Trifan, M.D., Ph.D., Vice President for Clinical Development, presented preclinical data supporting the development of the Company's proprietary CD40 agonistic antibody, APX005M, at a poster session at the 30th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2015), taking place November 4-8 at the Gaylord National Resort & Convention Center in National Harbor, Maryland. APX005M, currently in Phase 1...
↧